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Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem
cell disorders characterized by ineffective hematopoiesis, peripheral cytopenias, frequent
karyotypic abnormalities, and risk of transformation to acute myeloid leukemia (AML) [1–5].
MDS are rare in young people, and median age of patients with MDS is approximately 70 years
[6, 7]. Current management in MDS includes supportive care, drug therapy, and allogeneic
stem cell transplantation. MDS patients older than age 70 years are not good candidates for
allogeneic stem cell transplantation [8, 9]. The major complication of MDS patients after
allogeneic stem cell transplantation with reduced intensity conditioning is relapse of malignant
disease. Relapse can be predicted by monitoring of Wilms’ tumor 1 (WT1) gene expression by
real-time PCR and CD34+ donor chimerism analysis [10].
Single-nucleotide polymorphism array (SNP-A) analysis, standard metaphase cytogenetics,
and rapid progress in flow cytometric analysis, genes mutation analysis, and gene expression
profiling have identified key deregulated genes and signaling pathways important for accurate
prognostication and risk stratification for individual patients with MDS [11–18]. The initial
French–British–American (FAB) classification system of MDS was published in 1982 [19] and
was later refined to the International Prognostic Scoring System (IPSS) [20] and to World
Health Organization (WHO) Prognostic Scoring System (WPSS) [21, 22]. The new revised IPSS
(IPSS-R) integrated marrow cytogenetic subset, marrow blast percentage, and depth of
cytopenias (hemoglobin, platelet, and absolute neutrophil count) and was published in 2012
[23]. Validation of WPSS for MDS and comparison with IPSS-R has been recently described
[24]. Two other prognostic systems for MDS subgroups (M.D. Anderson lower risk MDS
prognostic scoring system; chronic myelomonocytic leukemia /CMML/ prognostic scoring
system) exist [18, 25].
In lower risk MDS, treatment focuses on amelioration of consequences of cytopenias and
transfusions and improving of quality of life. The first line of therapy of lower risk MDS with
normal chromosome 5 is treatment with erythropoiesis-stimulating agents (erythropoietin)
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with or without of granulocyte colony-stimulating factor [26]. Transfusion-dependent lower
risk MDS patients with del(5q) are treated with immunomodulatory or cereblon-binding drug
lenalidomide [27]. Thrombocytopenia occurring sometimes in combination with anemia or
without anemia can be treated with romiplostin (thrombopoietin agonist) [27]. Neutropenia
is treated with growth factors (G-CSF and GM-CSF) [27]. Higher-risk MDS if untreated have
median survival only about 12 months. Two hypomethylating agents (azacitidine and
decitabine) inhibit DNA methyltransferases 3A and 3B and reverse the aberrant methylation
involved in MDS progression to AML. The development of novel therapeutic strategies in
MDS is dependent on recent advances in the molecular pathogenesis of MDS [6, 16, 28–39].
Various combination therapies in MDS are also intensively studied [27, 40, 41].
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